DiagnaMed Holdings Corp. announced a clinical validation milestone of the BRAIN AGE® Brain Health AI Platform (?BRAIN AGE®?), a world-first consumer brain health and wellness AI solution that estimates brain age and provides a brain health score, with a first-of-a-kind peer-reviewed paper in Frontiers in Neuroergonomics, titled ?Brain-age estimation with a low-cost EEG-headset: effectiveness and implications for large-scale screening and brain optimization?.
With funding support from DiagnaMed, researchers from Drexel University?s Creativity Research Lab and Stockton University, under an IRB-approved research study, developed an artificial intelligence technique that can effectively estimate an individual?s brain age based on electroencephalogram (EEG) brain scans. The technology could help to make early, regular screening for degenerative brain diseases more accessible. The research was led by John Kounios, PhD, professor in Drexel?s College of Arts and Sciences and Creativity Research Lab director, and the research team used a type of artificial intelligence called machine learning to estimate an individual?s brain age similar to the way one might guess another person?s age based on their physical appearance. BRAIN AGE® has several promising applications for the millions of individuals and placements in up to 10,000 licensed physicians, specialists and sports clinics in North America focusing on health and wellness, sports and physical therapy, mental health, chiropractic care, or clinical and academic research for neurological and cognitive disorders. The Company believes that the potential initial target market population for BRAIN AGE®, comprised of healthy individuals, athletes, mental health and neurodegenerative patients, is at least 50 million in the U.S. alone. BRAIN AGE® can be used as a screening tool to identify individuals whose brain-age gap suggests the possibility of underlying age-related pathology that can be followed up with specific diagnostic tests. Furthermore, it can be performed repeatedly to verify results and detect changes over time. This means that it may become practical to begin screening people in early middle age (or younger) rather than waiting for late middle age, or older, when symptoms become apparent. Essentially, BRAIN AGE® can raise the possibility of large-scale detection and treatment of the earliest phases of age-related neurological disorders rather than later. In addition, BRAIN AGE® may be a useful tool at home or in the workplace and for researchers and medical professionals who wish to test potential interventions for slowing or reversing neurological aging.